Phase III trial demonstrates that combination therapy improves progression-free survival in advanced NSCLC patients with KRAS mutations, suggesting enhanced treatment strategies.
Conclusions: This is the first prospective phase III trial showing osi plus CTx significantly prolongs PFS versus osi monotherapy in advanced EGFRm NSCLC with TP53 co-mutations.These findings suggest that this high-risk population might benefit more from combination therapy.Clinical trial identification: NCT04695925.
No takes yet. Share an insight, caveat, or question.
Paz-Ares et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: